PharmacoEconomics
Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis
Fei-Li Zhao, Feng Xie, Hao Hu, Shu-Chuen Li
Corresponding Author: Shu-Chuen Li, School of Biomedical Sciences & Pharmacy
University of Newcastle, Callaghan, NSW 2308, Australia.
E-mail:
Electronic Supplementary Material
AppendixS1. Electronic search strategy (Final searching date: August 5th, 2010)
((((indirect costs[Title/Abstract] ) OR cost of illness[Title/Abstract]) OR productivity costs[Title/Abstract]) OR human capital[Title/Abstract])
AND Diabetes [Keyword]
AND Asthma[Keyword]
ANDSchizophrenia [Keyword]
AND Rheumatoid arthritis [Keyword]
AppendixS2. Articles included in analysis and cost resutls (2009 US dollar)
Author / Disease / Country/Region / Year / Data Source / No of Subjects / Age
(Years) / Female
(%) / Duration
(Years) / Employed
(%) / Mortality(†)Caregiver (‡) IC / Indirect Cost* / Percent†
Mellis et al.[1] / AS / Australia / 1991 / Survey / / / / / / / / / / / / / 209 / 0.52%
Ungar et al.[2] / AS / Canada / 1998 / Survey / 940 / Classified / 66.3 / / / 52.2 / / / 1302 / 3.41%
Herjavecz et al.[3] / AS / Hungary / 2003 / Survey / 378 / 10 / 32/64 / / / / / ‡ / 990 / 4.00%
Herjavecz et al.[3] / AS / Hungary / 2003 / Survey / 711 / 39 / 32/64 / / / / / / / 751 / 5.27%
Antonicelli et al.[4] / AS / Italy / 2004 / Survey / 500 / 36.6 / 57.2 / / / 66.4 / / / 785 / 2.63%
Accordini et al.[5] / AS / Italy / 2006 / Survey / 527 / 32.2 / 51.6 / 16.8 / 71.4 / / / 487 / 1.63%
Dal Negro et al.[6] / AS / Italy / 2007 / Survey / 485 / 49.2 / 62 / 13.7 / 42.5 / / / 135 / 0.45%
Dal Negro et al.[6] / AS / Italy / 2007 / Survey / 485 / 49.2 / 62 / 13.7 / 42.5 / / / 273 / 0.91%
Lai et al.[7] / AS / Korea / 2006 / Survey / 401 / 29.9 / 59.1 / / / / / / / 78 / 0.28%
Lai et al.[7] / AS / Malaysia / 2006 / Survey / 401 / 28.7 / 53 / / / / / / / 127 / 0.85%
Lai et al.[7] / AS / Philippine / 2006 / Survey / 400 / 22.8 / 53.8 / / / / / / / 80 / 2.45%
Lai et al.[7] / AS / Singapore / 2006 / Survey / 400 / 25.2 / 54.8 / / / / / / / 297 / 0.57%
Lai et al.[7] / AS / Taiwan / 2006 / Survey / 396 / 32 / 46.8 / / / / / / / 208 / 0.65%
Lai et al.[7] / AS / China / 2006 / Survey / 399 / 43.9 / 51.5 / / / / / / / 73 / 1.11%
Lai et al.[7] / AS / Hong Kong / 2006 / Survey / 402 / 31.8 / 36.8 / / / / / / / 223 / 0.52%
Lai et al.[7] / AS / Vietnam / 2006 / Survey / 393 / 36.7 / 57.5 / / / / / / / 53 / 1.85%
Chew et al.[8] / AS / Singapore / 1999 / Database / / / / / / / / / / / / / 177 / 0.34%
Serra-B. et al.[9] / AS / Spain / 1998 / Survey / 333 / 42 / 64 / / / / / / / 2805 / 7.67%
Jansson et al.[10] / AS / Sweden / 2007 / Survey / 115 / 25-56 / 59 / 28days / / / / / 2240 / 6.12%
Szucs et al.[11] / AS / Switzerland / 1999 / Survey / 589 / 43.9 / / / 10.62 / 56 / ‡ / 1164 / 2.81%
Weiss et al.[12] / AS / USA / 1992 / Survey / / / / / / / / / / / †‡ / 468 / 0.45%
Smith et al.[13] / AS / USA / 1997 / Database / 4,693,600 / / / 55.4 / / / / / ‡ / 207 / 0.82%
Weiss et al.[14] / AS / USA / 2000 / Survey / / / / / / / / / / / †‡ / 473 / 3.97%
Leigh et al.[15] / AS / USA / 2002 / Database / / / / / / / / / / / †‡ / 379 / 1.02%
Gendo et al.[16] / AS / USA / 2003 / Survey / 638 / 9.4 / 40.1 / 4.9 / / / ‡ / 405 / 1.03%
Cisternas et al.[17] / AS / USA / 2003 / Survey / 401 / / / 71 / / / / / / / 2279 / 0.88%
Colice et al.[18] / AS / USA / 2006 / Database / 443 / 44.5 / 47 / / / 100 / / / 1825 / 4.96%
Dawson et al.[19] / DI / Canada / 2002 / Database / / / / / / / / / / / † / 1090 / 2.86%
Wang et al.[20] / DI / China / 2009 / Survey / 2040 / 64.2 / 57.4 / >1.0 / 15.5 / ‡ / 213 / 3.23%
Gonzalez et al.[21] / DI / Colombia / 2009 / Literature / / / / / / / / / / / † / 575 / 6.25%
Stock et al.[22] / DI / German / 2006 / Database / / / / / / / / / / / † / 2994 / 15.97%
Koster et al.[23] / DI / German / 2006 / Database / 26,971 / / / / / / / / / / / 5445 / 8.78%
Tharkar et al.[24] / DI / India / 2010 / Survey / 718 / 56 / 47.1 / Categorized / 46.9 / ‡ / 102 / 3.32%
Lucioni et al.[25] / DI / Italy / 2003 / Survey / 1263 / 65.7 / 50.2 / 13 / / / / / 2820 / 9.43%
Phillips et al.[26] / DI / Mexico / 1992 / Literature / / / / / / / / / / / / / 527 / 4.00%
Redekop et al.[27] / DI / Netherland / 2002 / Survey / 1371 / 65.2 / 51.3 / 6.7 / 19.5 / / / 98 / 0.25%
Jonsson [28] / DI / Sweden / 1983 / Database / / / / / / / / / † / 3268 / 8.93%
Olsson et al.[29] / DI / Sweden / 1994 / Database / 285 / 20-64 / / / / / / / / / 11490 / 31.39%
Henriksson et al.[30] / DI / Sweden / 1998 / Literature / / / / / / / / / † / 2060 / 5.63%
Norlund et al.[31] / DI / Sweden / 2001 / Survey / 1677 / 66.3 / 47 / 9.3 / 30 / / / 4888 / 13.36%
Huse et al.[32] / DI / USA / 1989 / Database / / / / / / / / / † / 2767 / 6.02%
Warner et al.[33] / DI / USA / 1996 / Database / / / / / / / / / † / 13948 / 30.32%
Ray et al.[34] / DI / USA / 1998 / Database / / / / / / / / / † / 3843 / 8.35%
Ng et al.[35] / DI / USA / 2001 / Database / 1351 / / / 53 / / / 52.9 / / / 10055 / 21.86%
Hogan et al.[36] / DI / USA / 2003 / Database / / / / / / / / / † / 3923 / 8.53%
Dall et al.[37] / DI / USA / 2009 / Database / / / / / / / / / † / 3438 / 7.48%
Tao et al.[38] / DI / USA / 2010 / Database / 817 / 48.44 / 56 / / / / / / / 7869 / 17.11%
Azevedo et al.[39] / RA / Brazil / 2008 / Survey / 192 / 47.37 / 85.9 / 9.79 / 43.2 / / / 2666 / 26.40%
Maetzel et al.[40] / RA / Canada / 2004 / Survey / 253 / 57.1 / 79.8 / / / 30.8 / ‡ / 5220 / 13.67%
Fautrel et al.[41] / RA / Canada / 2007 / Survey / 121 / 57.4 / 79.3 / 13.1 / 33.6 / / / 10904 / 28.55%
Puolakka et al.[42] / RA / Finland / 2006 / Database / 162 / / / 62.3 / <1.0 / 62.3 / / / 8138 / 23.87%
Kobelt et al.[43] / RA / France / 2008 / Survey / 1487 / 62.7 / 83.5 / 18 / 17.6 / / / 1058 / 3.25%
Merkesdal et al.[44] / RA / German / 2001 / Survey / 133 / 47 / 86 / <1.0 / 100 / / / 16066 / 36.05%
Merkesdal et al.[45] / RA / German / 2005 / Survey / 234 / 53 / 76 / 8 / 38 / / / 1627 / 47.12%
Huscher et al.[46] / RA / German / 2006 / Database / 4351 / 53 / 78.9 / / / 45 / / / 10308 / 4.77%
Hulsemann et al.[47] / RA / German / 2006 / Survey / 340 / 58.4 / 76 / 8.4 / / / / / 15813 / 46.37%
Pentek et al.[48] / RA / Hungary / 2007 / Survey / 257 / 55 / 86 / 9.06 / 23 / / / 3016 / 16.05%
Leardini et al.[49] / RA / Italy / 2002 / Survey / 200 / 55.3 / 86 / 12.6 / 18.5 / ‡ / 4663 / 15.60%
Verstappen et al.[50] / RA / Netherland / 2005 / Survey / 576 / 59 / 72.4 / 7 / 40 / / / 8455 / 21.41%
Jonsson et al.[51] / RA / Sweden / 1992 / Survey / 82 / / / 35.4 / 19 / / / / / 7750 / 21.18%
Hallert et al.[52] / RA / Sweden / 2004 / Survey / 211 / 55 / 69.2 / <1.0 / / / / / 9483 / 25.91%
Kobelt et al.[53] / RA / Sweden / 2005 / Survey / 616 / 64.5 / 74.2 / 17.7 / 17.7 / / / 9154 / 25.01%
Hallert et al.[54] / RA / Sweden / 2006 / Survey / 211 / 55 / 69.2 / <1.0 / / / / / 9624 / 26.30%
Jacobsson et al.[55] / RA / Sweden / 2007 / Survey / 613 / 66 / 73.9 / 16.7 / 21 / / / 9222 / 25.20%
Soderlin et al.[56] / RA / Sweden / 2003 / Survey / 13 / 58 / 54 / <1.0 / 61 / / / 3159 / 8.63%
Kobelt et al.[57] / RA / Sweden / 2002 / Survey / 183 / 52.4 / 63.4 / <1.0 / / / / / 7151 / 19.54%
Kobelt et al.[57] / RA / UK / 2002 / Survey / 916 / 54.8 / 66.6 / <1.0 / / / / / 4142 / 11.90%
McIntosh[58] / RA / UK / 1996 / Database / / / / / / / / / / / / / 7814 / 22.46%
Meenan et al.[59] / RA / USA / 1978 / Survey / 50 / 48 / 76 / 9.8 / 76 / / / 25676 / 20.13%
Gabriel et al.[60] / RA / USA / 1997 / Survey / 123 / 61.1 / 68.1 / / / / / / / 3469 / 55.82%
Newhall-P. et al.[61] / RA / USA / 2000 / Survey / 150 / 51 / 80 / <1.0 / 52 / / / 4881 / 7.54%
Birnbaum et al.[62] / RA / USA / 2010 / Database / / / / / / / / / / / ‡ / 9260 / 10.61%
Osiri et al.[63] / RA / Thailand / 2007 / Survey / 158 / 53.2 / 95.6 / 10.3 / 48.7 / ‡ / 662 / 8.08%
Carr et al.[64] / SC / Australia / 2003 / Survey / / / / / / / / / 14.5-male 17-female / ‡ / 19951 / 49.88%
Fitzgerald et al.[65] / SC / Australia / 2007 / Survey / 347 / 33.89 / 38 / / / 24-male 11-female / / / 11845 / 29.61%
Grover et al.[66] / SC / India / 2005 / Survey / 50 / 32.92 / 38 / 5-10 / 46 / ‡ / 9471 / 305.52%
Tarricone et al.[67] / SC / Italy / 2000 / Survey / 99 / 42 / 50.5 / Categorized / 15.2 / ‡ / 29862 / 99.87%
Percudani et al.[68] / SC / Italy / 2004 / Survey / 50 / 44.5 / 26 / Categorized / 12 / ‡ / 10282 / 34.39%
Chang et al.[69] / SC / Korea / 2008 / Database / / / / / / / / / / / †‡ / 17972 / 63.96%
Evers et al.[70] / SC / Netherland / 1995 / Database / / / / / / / / / / / / / 10008 / 25.34%
Lindstrom et al.[71] / SC / Sweden / 2007 / Survey / 225 / 38.5 / 41.3 / / / 25 / / / 33915 / 92.66%
Lee et al.[72] / SC / Taiwan / 2008 / Survey / 74 / 33.7 / 43.2 / 9.8 / / / ‡ / 18621 / 58.19%
Davies et al.[73] / SC / UK / 1990 / Literature / / / / / / / / / / / / / 21682 / 101.89%
Guest et al.[74] / SC / UK / 1999 / Literature / / / / / / / / / / / †‡ / 24605 / 62.31%
Mangalore et al.[75] / SC / UK / 2007 / Database / / / / / / / / / / / ‡ / 35457 / 70.70%
Muller et al.[76] / SC / USA / 1983 / Database / / / / / / / / / / / / / 26290 / 57.15%
Wu et al.[77] / SC / USA / 2005 / Database / / / / / / / / / / / †‡ / 26273 / 57.12%
*Indirect Cost, annual indirect cost per patient
† Annual indirect cost per patient expressed as percentage of GDP per catpita
†,mortality costs identified in literature; ‡, caregiver costs identified in literature; /, not identified in the literature
AS, asthma; DI, diabetes; RA, rheumatoid arthritis; SC, schizophrenia; IC, indirect cost.
Reference:
1.Mellis CM, Peat JK, Bauman AE, Woolcock AJ. The cost of asthma in New South Wales. Med J Aust. 1991 Oct 21;155(8):522-8.
2.Ungar WJ, Coyte PC, Chapman KR, MacKeigan L. The patient level cost of asthma in adults in south central Ontario. Pharmacy Medication Monitoring Program Advisory Board. Can Respir J. 1998 Nov-Dec;5(6):463-71.
3.Herjavecz I, Nagy GB, Gyurkovits K, Magyar P, Dobos K, Nagy L, et al. Cost, morbidity, and control of asthma in Hungary: The Hunair Study. J Asthma. 2003 Sep;40(6):673-81.
4.Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004 May;23(5):723-9.
5.Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol. 2006;141(2):189-98.
6.Dal Negro RW, Micheletto C, Tosatto R, Dionisi M, Turco P, Donner CF. Costs of asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study. Respir Med. 2007 Dec;101(12):2511-9.
7.Lai CKW, Kim YY, Kuo SH, Spencer M, Williams AE. Cost of asthma in the Asia-Pacific region. European Respiratory Review. 2006;15(98):10-6.
8.Chew FT, Goh DY, Lee BW. The economic cost of asthma in Singapore. Aust N Z J Med. 1999 Apr;29(2):228-33.
9.Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J. 1998 Dec;12(6):1322-6.
10.Jansson SA, Ronmark E, Forsberg B, Lofgren C, Lindberg A, Lundback B. The economic consequences of asthma among adults in Sweden. Respir Med. 2007 Nov;101(11):2263-70.
11.Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J. 1999 Feb;13(2):281-6.
12.Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med. 1992 Mar 26;326(13):862-6.
13.Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):787-93.
14.Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol. 2000 Sep;106(3):493-9.
15.Leigh JP, Romano PS, Schenker MB, Kreiss K. Costs of occupational COPD and asthma. Chest. 2002 Jan;121(1):264-72.
16.Gendo K, Sullivan SD, Lozano P, Finkelstein JA, Fuhlbrigge A, Weiss KB. Resource costs for asthma-related care among pediatric patients in managed care. Ann Allergy Asthma Immunol. 2003 Sep;91(3):251-7.
17.Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003 Jun;111(6):1212-8.
18.Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med. 2006 Aug;48(8):794-802
19.Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH. The economic cost of diabetes in Canada, 1998. Diabetes Care. 2002 Aug;25(8):1303-7.
20.Wang W, McGreevey WP, Fu C, Zhan S, Luan R, Chen W, et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care. 2009 Sep;15(9):593-601.
21.Gonzalez JC, Walker JH, Einarson TR. Cost-of-illness study of type 2 diabetes mellitus in Colombia. Rev Panam Salud Publica. 2009 Jul;26(1):55-63.
22.Stock SA, Redaelli M, Wendland G, Civello D, Lauterbach KW. Diabetes – prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med. 2006 Mar;23(3):299-305.
23.Koster I, von Ferber L, Ihle P, Schubert I, Hauner H. The cost burden of diabetes mellitus: the evidence from Germany – the CoDiM study. Diabetologia. 2006 Jul;49(7):1498-504.
24.Tharkar S, Devarajan A, Kumpatla S, Viswanathan V. The socioeconomics of diabetes from a developing country: A population based cost of illness study. Diabetes Res Clin Pract. 2010 Jun 8;89(3):334-40.
25.Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G, CODE-2 Italian Advisory Board. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol. 2003;2(2):121-33.
26.Phillips M, Salmeron J. Diabetes in Mexico – a serious and growing problem. World Health Stat Q. 1992;45(4):338-46.
27.Redekop WK, Koopmanschap MA, Rutten GE, Wolffenbuttel BH, Stolk RP, Niessen LW. Resource consumption and costs in Dutch patients with type 2 diabetes mellitus. Results from 29 general practices. Diabet Med. 2002 Mar;19(3):246-53.
28.Jonsson B. Diabetes – the cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand Suppl. 1983;671:19-27.
29.Olsson J, Persson U, Tollin C, Nilsson S, Melander A. Comparison of excess costs of care and production losses because of morbidity in diabetic patients. Diabetes Care. 1994 Nov;17(11):1257-63.
30.Henriksson F, Jonsson B. Diabetes: the cost of illness in Sweden. J Intern Med. 1998 Dec;244(6):461-8.
31.Norlund A, Apelqvist J, Bitzen PO, Nyberg P, Schersten B. Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered. J Intern Med. 2001 Jul;250(1):57-65.
32.Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of non-insulin-dependent diabetes mellitus. JAMA. 1989 Nov 17;262(19):2708-13.
33.Warner DC, McCandless RR, De Nino LA, Cornell JE, Pugh JA, Marsh GM. Costs of diabetes in Texas, 1992. Diabetes Care. 1996 Dec;19(12):1416-9.
34.Ray NF, Thamer M, Gardner E, Chan JK, Kahn R. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. Diabetes Care. 1998 Feb;21(2):296-309.
35.Ng YC, Jacobs P, Johnson JA. Productivity losses associated with diabetes in the US. Diabetes Care. 2001 Feb;24(2):257-61.
36.Hogan P, Dall T, Nikolov P, American Diabetes A. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003 Mar;26(3):917-32.
37.Dall TM, Mann SE, Zhang Y, Quick WW, Seifert RF, Martin J, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag. 2009 Apr;12(2):103-10.
38.Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. PLoS One. 2010;5(7):e11501.
39.de Azevedo AB, Ferraz MB, Ciconelli RM. Indirect costs of rheumatoid arthritis in Brazil. Value Health. 2008 Sep-Oct;11(5):869-77.
40.Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C, Community H, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis. 2004 Apr;63(4):395-401.
41.Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, et al. Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method. Med Decis Making. 2007 Mar-Apr;27(2):138-50.
42.Puolakka K, Kautiainen H, Pekurinen M, Mottonen T, Hannonen P, Korpela M, et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis. 2006 Jul;65(7):899-904.
43.Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine. 2008 Jul;75(4):408-15.
44.Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 2001 Mar;44(3):528-34.
45.Merkesdal S, Ruof J, Huelsemann JL, Mittendorf T, Handelmann S, Mau W, et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum. 2005 Apr 15;53(2):234-40.
46.Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006 Sep;65(9):1175-83.
47.Hulsemann JL, Ruof J, Zeidler H, Mittendorf T. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol Int. 2006 Jun;26(8):704-11.
48.Pentek M, Kobelt G, Czirjak L, Szekanecz Z, Poor G, Rojkovich B, et al. Costs of rheumatoid arthritis in Hungary. J Rheumatol. 2007 Jun;34(6):1437.
49.Leardini G, Salaffi F, Montanelli R, Gerzeli S, Canesi B. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol. 2002 Jul-Aug;20(4):505-15.
50.Verstappen SM, Boonen A, Verkleij H, Bijlsma JW, Buskens E, Jacobs JW, et al. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis. 2005 Dec;64(12):1754-60.
51.Jonsson B, Rehnberg C, Borgquist L, Larsson SE. Locomotion status and costs in destructive rheumatoid arthritis. A comprehensive study of 82 patients from a population of 13,000. Acta Orthop Scand. 1992 Apr;63(2):207-12.
52.Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology (Oxford). 2004 Nov;43(11):1374-82.
53.Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford). 2005 Sep;44(9):1169-75.
54.Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford). 2006 Mar;45(3):325-31.
55.Jacobsson LT, Lindroth Y, Marsal L, Juran E, Bergstrom U, Kobelt G. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand J Rheumatol. 2007 May-Jun;36(3):179-83.
56.Soderlin MK, Kautiainen H, Jonsson D, Skogh T, Leirisalo-Repo M. The costs of early inflammatory joint disease: a population-based study in southern Sweden. Scand J Rheumatol. 2003;32(4):216-24.
57.Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002 Sep;46(9):2310-9.
58.McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol. 1996 Aug;35(8):781-90.
59.Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum. 1978 Sep-Oct;21(7):827-33.
60.Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol. 1997 Jan;24(1):43-8.
61.Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol. 2000 May;27(5):1156-63.
62.Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis (RA) in the United States: methodology for incorporating intangible costs. Curr Med Res Opin. 2010;26(1):77-90.
63.Osiri M, Maetzel A, Tugwell P. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand. J Rheumatol. 2007 Jan;34(1):57-63.
64.Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry. 2003 Feb;37(1):31-40.
65.Fitzgerald PB, Montgomery W, de Castella AR, Filia KM, Filia SL, Christova L, et al. Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: economics. Aust N Z J Psychiatry. 2007 Oct;41(10):819-29.
66.Grover S, Avasthi A, Chakrabarti S, Bhansali A, Kulhara P. Cost of care of schizophrenia: a study of Indian out-patient attenders. Acta Psychiatr Scand. 2005 Jul;112(1):54-63.
67.Tarricone R, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Interdisciplinary Study Group on the Economic Impact of Schizophrenia. Health Policy. 2000 Feb;51(1):1-18.
68.Percudani M, Barbui C, Beecham J, Knapp M. Routine outcome monitoring in clinical practice: service and non-service costs of psychiatric patients attending a Community Mental Health Centre in Italy. Eur Psychiatry. 2004 Dec;19(8):469-77.
69.Chang SM, Cho SJ, Jeon HJ, Hahm BJ, Lee HJ, Park JI, et al. Economic burden of schizophrenia in South Korea. J Korean Med Sci. 2008 Apr;23(2):167-75.
70.Evers SM, Ament AJ. Costs of schizophrenia in The Netherlands. Schizophr Bull. 1995;21(1):141-53.
71.Lindstrom E, Eberhard J, Neovius M, Levander S. Costs of schizophrenia during 5 years. Acta Psychiatr Scand Suppl. 2007(435):33-40.
72.Lee IH, Chen PS, Yang YK, Liao YC, Lee YD, Yeh TL, et al. The functionality and economic costs of outpatients with schizophrenia in Taiwan. Psychiatry Res. 2008 Apr 15;158(3):306-15.
73.Davies L, Drummon M. The economic burden of schizophrenia. Psychiatric Bulletin. 1990;14:522-5.
74.Guest JF, Cookson RF. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics. 1999 Jun;15(6):597-610.
75.Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007 Mar;10(1):23-41.
76.Muller CF, Caton CL. Economic costs of schizophrenia: a postdischarge study. Med Care. 1983 Jan;21(1):92-104.
77.Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005 Sep;66(9):1122-9.